References
- Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O'Brien PC. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 2001; 285: 60–66
- Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998; 279: 1100–1107
- Lee TSW, Lee TD, Lombroso PJ, King RA. Atomoxetine and tics in ADHD. J Am Acad Child Adolesc Psychiatry 2004; 43: 1068–1069
- Spiller HA, Lintner CP, Winter ML. Atomoxetine (Strattera) exposure in children (abstract). J Toxicol Clin Toxicol 2004; 42: 720
- Caballero J, Nahata MC. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. Clin Ther 2003; 25: 3065–3083
- Anonymous. Atomoxetine (Strattera) revisited. Medical Letter on Drugs & Therapeutics 2004; 46: 65
- Henderson TA, Hartman K. Aggression, mania, and hypomania induction associated with atomoxetine. Pediatrics 2004; 114: 895–896
- Farid NA, Bergstrom RF, Ziege EA, Parli CJ, Lemberger L. Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. J Clin Pharmacol 1985; 25: 296–301
- Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metabolism & Disposition 2002; 30: 319–323
- Belle DJ, Ernest CS, Sauer JM, et al. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 2002; 42: 1219–1227
- Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998; 155: 1325–1331
- Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27: 699–711
- Extein I. Methylphenidate-induced choreoathetosis. Am J Psychiatry 1978; 135: 252–253
- Weiner WJ, Nausieda PA, Klawans HL. Methylphenidate-induced chorea: case report and pharmacologic implications. Neurology 1978; 28: 1041–1044
- Klawans HL, Weiner WJ. The effect of d-amphetamine on choreiform movement disorders. Neurology 1974; 24: 312–318
- Mattson RH, Calverley JR. Dextroamphetamine-sulfate-induced dyskinesias. JAMA 1968; 204: 400–402
- Burd L, Kerbeshian J. Stuttering and stimulants. J Clin Psychopharmacol 1991; 11: 72–73
- Boyer EW, Shannon M. The Serotonin Syndrome. N Engl J Med 2005; 352: 1112–1120
- Sauer JM, Long AJ, Ring B, Gillespie JS, Sanburn ND, DeSante KA, Petullo D, VandenBranden MR, Jensen CB, Wrighton SA, Smith BP, Read HA, Witcher JW. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. Journal of Pharmacology & Experimental Therapeutics 2004; 308: 410–418